Skip to main content
SpringerLink
Log in

The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma

  • Reviews
  • Published:
International Journal of Clinical and Laboratory Research

Summary

Lytic bone lesions and hypercalcemia are common features of multiple myeloma. In contrast, they are exceptional in other B-cell malignancies. Myeloma bone involvement is related to an uncoupling process associating increased osteoclastic resorption with decreased bone formation. Several osteoclast-activating factors, such as interleukin-1, macrophage colony-stimulating factor, and interleukin-6, are involved in this process. However, interleukin-6, the major myeloma cell growth factor, plays a critical role in myeloma-induced bone resorption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ascari E, Attardo-Parrinello G, Merlini G, Treatment of painful bone lesions and hypercalcemia. Eur J Haematol 43:135, 1989

    Article  Google Scholar 

  2. Bataille R, Klein B, The bone resorbing activity of interleukin-6. J Bone Miner Res 1991 (in press)

  3. Bataille R, Sany J, Clinical evaluation of myeloma osteoclastic bone lesions. II. Induced hypocalcemia test using salmon calcitonin. Metab Bone Dis Relat Res 4:39, 1982

    Article  PubMed  CAS  Google Scholar 

  4. Bataille R, Legendre O, Sany J, Acute effects of salmon calcitonin in multiple myeloma: a valuable method for serial evaluation of osteoclastic lesions and disease activity. A prospective study of 125 patients. J Clin Oncol 3:229, 1985

    PubMed  CAS  Google Scholar 

  5. Bataille R, Chappard D, Alexandre C, Sany J, Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 53:805, 1986

    PubMed  CAS  Google Scholar 

  6. Bataille R, Delmas P, Sany J, Serum bone gla-protein (osteocalcin) in multiple myeloma. Cancer 59:329, 1987

    Article  PubMed  CAS  Google Scholar 

  7. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C, Mechanism of bone destruction in multiple myeloma. The importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7:1909, 1989

    PubMed  CAS  Google Scholar 

  8. Bataille R, Jourdan M, Zhang XG, Klein B, Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008, 1989

    Article  PubMed  CAS  Google Scholar 

  9. Bataille R, Chappard D, Marcelli C, Rossi JF, Dessauw P, Baldet P, Sany J, Alexandre C, Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 76:484, 1990

    Article  PubMed  CAS  Google Scholar 

  10. Bataille R, Delmas PD, Chappard D, Sany J, Abnormal serum bone gla protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer 66:167, 1990

    Article  PubMed  CAS  Google Scholar 

  11. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C, The recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:62, 1991

    Article  PubMed  CAS  Google Scholar 

  12. Bot FJ, Eijk L, van Broeders L, Aarden LA, Lowenberg B, Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells. Blood 73:435, 1989

    PubMed  CAS  Google Scholar 

  13. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zambonin-Zallone A, Marchisio PC, Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688, 1991

    PubMed  CAS  Google Scholar 

  14. Canalis E, McCarthy T, Centrella M, Growth factors and the regulation of bone remodelling. J Clin Invest 81:277, 1988

    Article  PubMed  CAS  Google Scholar 

  15. Chappard D, Rossi JF, Bataille R, Alexandre C, Cytomorphometry of osteoclasts demonstrates an abnormal population in B-cell malignancies but not in multiple myeloma. Calcif Tissue Int 48:13, 1991

    Article  PubMed  CAS  Google Scholar 

  16. Charhon S, Le myélome multiple à forme ostéocondensante—à propos de deux observations personnelles et revue de la literature. Thèse de medicine, Lyon, France 1979

  17. Delmas PD, Charmon S, Chapuy MC, Vignon E, Briancon D, Edouard C, Meunier PJ, Long-term effects of dichloromethylene diphosphonate (Cl2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 4:163, 1982

    Article  CAS  Google Scholar 

  18. Durie BGM, Salmon SE, Mundy GR, Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol 47:21, 1981

    Article  PubMed  CAS  Google Scholar 

  19. Gailani S, McLimans WF, Mundy GR, Nussbaum A, Roholt O, Zeigel R, Controlled environment culture of bone marrow explants from human myeloma. Cancer Res 36:1299, 1976

    PubMed  CAS  Google Scholar 

  20. Garrett IR, Durie BGM, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR, Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317:526, 1987

    Article  PubMed  CAS  Google Scholar 

  21. Gozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw R, Lansdorp AR, Di Guglielmo R, Production of interleukin-1 by bone marrow myeloma cells. Blood 74:380, 1989

    Google Scholar 

  22. Grauer JL, Blanc D, Zagala A, Sotto JJ, Duplan B, Drevet JG, Phelip X, L'histomorphométrie osseuse dans les dysglobulinémies monoclonales. Rev Rhum Mal Osteoartic 53:517, 1986

    PubMed  CAS  Google Scholar 

  23. Josse RG, Murray TM, Mundy GR, Jez D, Heershche JNM, Observation of the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor. J Clin Invest 67:1472, 1981

    Article  PubMed  CAS  Google Scholar 

  24. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T, Autocrine generation and essential requirement of BSF/2 IL-6 for human multiple myeloma. Nature 322:73, 1988

    Google Scholar 

  25. Kawano M, Yamamoto I, Iwato K, Tanaka H, Asaoku H, Tanabe O, Ishikawa H, Nobuyoshi M, Ohmoto Y, Hirai Y, Kuramoto A, Interleukin-I beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 73:1646, 1989

    PubMed  CAS  Google Scholar 

  26. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R, Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by Interleukin-6. Blood 73:517, 1989

    PubMed  CAS  Google Scholar 

  27. Klein B, Widjenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clément C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R, Murine, anti-Interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991 (in press)

  28. Luger TA, Kruttman J, Kirnbauer R, Urbanski A, Schwarz T, Klappacher G, Köck A, Micksche M, Malejczyk J, Schauer E, May LT, Sengal PB, IFN β2/IL-6 augments the activity of human natural killer cells. J Immunol 143:1206, 1989

    PubMed  CAS  Google Scholar 

  29. MacDonald BR, Mundy GR, Clark S, Wang EA, Kuehl TJ, Stanley ER, Roodman GD, Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J Bone Miner Res 1:227, 1986

    Article  PubMed  CAS  Google Scholar 

  30. Macro M, Troussard X, Galateau F, Renan O, Leporrier M, Loyau G, Myélome ostéocondensant diffus avec localisation thyroïdienne. Rev Rhum Mol Osteoartic 56:613, 1989

    CAS  Google Scholar 

  31. Marcelli C, Chappard D, Rossi JF, Jaubert J, Alexandre C, Dessauw P, Baldet P, Bataille R, Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma. Cancer 62:1163, 1988

    Article  PubMed  CAS  Google Scholar 

  32. Meszaros WT, The many facets of multiple myeloma. Semin Roentgenol IX:219, 1974

    Article  Google Scholar 

  33. Mundy GR, Bertolini DR, Bone destruction and hypercalemia in plasma cell myeloma. Semin Oncol 13:291, 1986

    PubMed  CAS  Google Scholar 

  34. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE, Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041, 1974

    Article  PubMed  CAS  Google Scholar 

  35. Nakamura M, Merchav S, Carter A, Ernst TJ, Demetri GD, Furukawa Y, Anderson K, Expression of a novel 3–5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol 143:3543, 1989

    PubMed  CAS  Google Scholar 

  36. Paterson AD, Kanis JA, Cameron EC, Douglas DL, Beard DJ, Preston FE, Russell RGG, The use of dichloromethylene diphosphonate for the management of hypercalcemia in multiple myeloma. Br J Haematol 54:121, 1983

    Article  PubMed  CAS  Google Scholar 

  37. Portier M, Rajzbaum G, Zhang XG, Attal M, Rusalen C, Maraninchi D, Widjenes J, Manonni P, Piechaczyck M, Bataille R, Klein B, In vivo paracrine but not autocrine interleukin-6 gene expression in multiple myeloma. Eur J Immunol 21:1759, 1991

    Article  PubMed  CAS  Google Scholar 

  38. Radl J, Croese JW, Zurcher C, Enden-Vieveen MHM van den, Brondijk RJ, Kazil M, Haaijman JJ, Reitsma PH, Bijvoet OLM, Influence of treatment with APD-biphosphonates on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 55:1030, 1985

    Article  PubMed  CAS  Google Scholar 

  39. Rodriguez LH, Finkelstein JB, Shullenberger CC, Alexanian R, Bone healing in multiple myeloma with melphalan chemotherapy. Ann Intern Med 76:551, 1972

    PubMed  CAS  Google Scholar 

  40. Rossi JF, Bataille R, In vitro osteolytic activity of human myeloma plasma cells and the clinical evaluation of myeloma osteoclastic bone lesions. Br J Cancer 50:119, 1984

    PubMed  CAS  Google Scholar 

  41. Rossi JF, Bataille R, Chappard D, Alexandre C, Janbon C, Unusual B cell malignancies presenting unusual bone involvement and mimicking multiple myeloma. A personal study of 9 cases. Am J Med 83:10, 1987

    Article  PubMed  CAS  Google Scholar 

  42. Rossi JF, Chappard D, Marcelli C, Baldet P, Alexandre C, Janbon C, Jourdan J, Bataille R, Micro-osteoclastic resorption as a characteristic feature of B-cell malignancies other than multiple myeloma. Br J Haematol 76:469, 1990

    Article  PubMed  CAS  Google Scholar 

  43. Schecter GP, Wahl LM, Horton JE, In vitro bone resorption by human myeloma cells. In: Potter M (ed) Progress in myeloma. Biology of myeloma. pp 67–77, 1980

  44. Siris ES, Sherman WH, Baquiran DC, Schlatterer JP, Osserman EF, Canfield RF, Effects of chloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med 302:310, 1980

    Article  PubMed  CAS  Google Scholar 

  45. Smyth MJ, Ortaldo JR, Comparison of the effect of IL-2 and IL-6 on the lytic activity of purified human peripheral blood large granular lymphocytes. J Immunol 146:1380, 1991

    PubMed  CAS  Google Scholar 

  46. Uchida A, Yagital M, Sugiyama H, Hoshino T, Moore M, Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer 34:375, 1984

    Article  PubMed  CAS  Google Scholar 

  47. Udagawa N, Takahashi N, Aktsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T, Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone-marrow derived stromal cells. Proc Natl Acad Sci USA 87:7260, 1990

    Article  PubMed  CAS  Google Scholar 

  48. Valentin-Opran A, Charmon SA, Meunier PJ, Edouard CM, Arlot ME, Quantitative histology of myeloma-induced bone changes. Br J Haematol 52:601, 1982

    Article  PubMed  CAS  Google Scholar 

  49. Warren MK, Ralph P, Macrophage growth factor CSF-I stimulates human monocyte production of interferon, tumor necrosis factor and colony-stimulating activity. J Immunol 137:2281, 1986

    PubMed  CAS  Google Scholar 

  50. Wieczorek AJ, Belch AR, Jacobs A, Bowen D, Padua RA, Paietta E, Stanley ER, Increased circulating colony-stimulating factor-1 in patients with pre-leukemia, leukemia and lymphoid malignancies. Blood 77:1796, 1991

    Google Scholar 

  51. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW, Ansari AA, Sell KW, Stanley ER, Total absence of colony-stimulating factor-1 in the macrophage deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 87:4828, 1990

    Article  PubMed  CAS  Google Scholar 

  52. Yamamoto I, Kawano M, Sone T, et al., Production of interleukin-1 β, a potent bone resorbing cytokine, by cultured myeloma cells, Cancer Res 49:4242, 1989

    PubMed  CAS  Google Scholar 

  53. Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R, Mundy GR, Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia and leukocytosis in a human tumor in male mice. J Clin Invest 87:977, 1991

    Article  PubMed  CAS  Google Scholar 

  54. Zhang XG, Klein B, Bataille R, Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74:11, 1989

    PubMed  CAS  Google Scholar 

  55. Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B, Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human multiple myeloma cells. Blood 76:2599, 1990

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunorhumatologie and INSERM U 291, Centre Gui de Chauliac, Hôpital Saint-Eloi, F-34059, Montpellier, France

    Régis Bataille & Bernard Klein

  2. LBTO Faculté de Médecine, F-42023 Cadex 2, Saint-Etienne, France

    Daniel Chappard

Authors
  1. Régis Bataille
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Chappard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernard Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bataille, R., Chappard, D. & Klein, B. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma. Int J Clin Lab Res 21, 283–287 (1992). https://doi.org/10.1007/BF02591662

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02591662

Key words

Search

Navigation